Does Higher Gadolinium Concentration Play a Role in the Morphologic Assessment of Brain Tumors? Results of a Multicenter Intraindividual Crossover Comparison of Gadobutrol versus Gadobenate Dimeglumine (the MERIT Study)
Gadobenate dimeglumine has proved advantageous compared with other gadolinium-based contrast agents for contrast-enhanced brain MR imaging. Gadobutrol is a more highly concentrated agent (1.0 mol/L). This study intraindividually compared 0.1-mmol/kg doses of these agents for qualitative and quantita...
Saved in:
Published in | American journal of neuroradiology : AJNR Vol. 33; no. 6; pp. 1050 - 1058 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oak Brook, IL
American Society of Neuroradiology
01.06.2012
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Gadobenate dimeglumine has proved advantageous compared with other gadolinium-based contrast agents for contrast-enhanced brain MR imaging. Gadobutrol is a more highly concentrated agent (1.0 mol/L). This study intraindividually compared 0.1-mmol/kg doses of these agents for qualitative and quantitative evaluation of brain tumors.
Adult patients with suspected or known brain tumors underwent 2 identical MR imaging examinations at 1.5T, 1 with gadobenate dimeglumine and the other with gadobutrol, both at a dose of 0.1-mmol/kg body weight. The agents were injected in randomized order separated by 3-14 days. Imaging sequences and acquisition timing were identical for the 2 examinations. Three blinded readers evaluated images qualitatively for diagnostic information (lesion extent, delineation, morphology, enhancement, global preference) and quantitatively for CNR and LBR.
One hundred fourteen of 123 enrolled patients successfully underwent both examinations. Final diagnoses were intra-axial tumors, metastases, extra-axial tumors, "other" tumors, and "nontumor" (49, 46, 8, 7, and 4 subjects, respectively). Readers 1, 2, and 3 demonstrated preference for gadobenate dimeglumine in 46 (40.7%), 54 (47.4%), and 49 (43.0%) patients, respectively, compared with 6, 7, and 7 patients for gadobutrol (P < .0001, all readers). Highly significant (P < .0001, all readers) preference for gadobenate dimeglumine was demonstrated for all other qualitative end points. Inter-reader agreement was good for all evaluations (κ = 0.414-0.629). Significantly superior CNR and LBR were determined for gadobenate dimeglumine (P < .019, all readers).
Significantly greater morphologic information and lesion enhancement are achieved on brain MR imaging with 0.1-mmol/kg gadobenate dimeglumine compared with gadobutrol at an equivalent dose. |
---|---|
AbstractList | BACKGROUND AND PURPOSEGadobenate dimeglumine has proved advantageous compared with other gadolinium-based contrast agents for contrast-enhanced brain MR imaging. Gadobutrol is a more highly concentrated agent (1.0 mol/L). This study intraindividually compared 0.1-mmol/kg doses of these agents for qualitative and quantitative evaluation of brain tumors. MATERIALS AND METHODSAdult patients with suspected or known brain tumors underwent 2 identical MR imaging examinations at 1.5T, 1 with gadobenate dimeglumine and the other with gadobutrol, both at a dose of 0.1-mmol/kg body weight. The agents were injected in randomized order separated by 3-14 days. Imaging sequences and acquisition timing were identical for the 2 examinations. Three blinded readers evaluated images qualitatively for diagnostic information (lesion extent, delineation, morphology, enhancement, global preference) and quantitatively for CNR and LBR. RESULTSOne hundred fourteen of 123 enrolled patients successfully underwent both examinations. Final diagnoses were intra-axial tumors, metastases, extra-axial tumors, "other" tumors, and "nontumor" (49, 46, 8, 7, and 4 subjects, respectively). Readers 1, 2, and 3 demonstrated preference for gadobenate dimeglumine in 46 (40.7%), 54 (47.4%), and 49 (43.0%) patients, respectively, compared with 6, 7, and 7 patients for gadobutrol (P < .0001, all readers). Highly significant (P < .0001, all readers) preference for gadobenate dimeglumine was demonstrated for all other qualitative end points. Inter-reader agreement was good for all evaluations (κ = 0.414-0.629). Significantly superior CNR and LBR were determined for gadobenate dimeglumine (P < .019, all readers). CONCLUSIONSSignificantly greater morphologic information and lesion enhancement are achieved on brain MR imaging with 0.1-mmol/kg gadobenate dimeglumine compared with gadobutrol at an equivalent dose. BACKGROUND AND PURPOSE:Gadobenate dimeglumine has proved advantageous compared with other gadolinium-based contrast agents for contrast-enhanced brain MR imaging. Gadobutrol is a more highly concentrated agent (1.0 mol/L). This study intraindividually compared 0.1-mmol/kg doses of these agents for qualitative and quantitative evaluation of brain tumors.MATERIALS AND METHODS:Adult patients with suspected or known brain tumors underwent 2 identical MR imaging examinations at 1.5T, 1 with gadobenate dimeglumine and the other with gadobutrol, both at a dose of 0.1-mmol/kg body weight. The agents were injected in randomized order separated by 3-14 days. Imaging sequences and acquisition timing were identical for the 2 examinations. Three blinded readers evaluated images qualitatively for diagnostic information (lesion extent, delineation, morphology, enhancement, global preference) and quantitatively for CNR and LBR.RESULTS:One hundred fourteen of 123 enrolled patients successfully underwent both examinations. Final diagnoses were intra-axial tumors, metastases, extra-axial tumors, "other" tumors, and "nontumor" (49, 46, 8, 7, and 4 subjects, respectively). Readers 1, 2, and 3 demonstrated preference for gadobenate dimeglumine in 46 (40.7%), 54 (47.4%), and 49 (43.0%) patients, respectively, compared with 6, 7, and 7 patients for gadobutrol (P < .0001, all readers). Highly significant (P < .0001, all readers) preference for gadobenate dimeglumine was demonstrated for all other qualitative end points. Inter-reader agreement was good for all evaluations ( Kappa = 0.414-0.629). Significantly superior CNR and LBR were determined for gadobenate dimeglumine (P < .019, all readers).CONCLUSIONS:Significantly greater morphologic information and lesion enhancement are achieved on brain MR imaging with 0.1-mmol/kg gadobenate dimeglumine compared with gadobutrol at an equivalent dose. Gadobenate dimeglumine has proved advantageous compared with other gadolinium-based contrast agents for contrast-enhanced brain MR imaging. Gadobutrol is a more highly concentrated agent (1.0 mol/L). This study intraindividually compared 0.1-mmol/kg doses of these agents for qualitative and quantitative evaluation of brain tumors. Adult patients with suspected or known brain tumors underwent 2 identical MR imaging examinations at 1.5T, 1 with gadobenate dimeglumine and the other with gadobutrol, both at a dose of 0.1-mmol/kg body weight. The agents were injected in randomized order separated by 3-14 days. Imaging sequences and acquisition timing were identical for the 2 examinations. Three blinded readers evaluated images qualitatively for diagnostic information (lesion extent, delineation, morphology, enhancement, global preference) and quantitatively for CNR and LBR. One hundred fourteen of 123 enrolled patients successfully underwent both examinations. Final diagnoses were intra-axial tumors, metastases, extra-axial tumors, "other" tumors, and "nontumor" (49, 46, 8, 7, and 4 subjects, respectively). Readers 1, 2, and 3 demonstrated preference for gadobenate dimeglumine in 46 (40.7%), 54 (47.4%), and 49 (43.0%) patients, respectively, compared with 6, 7, and 7 patients for gadobutrol (P < .0001, all readers). Highly significant (P < .0001, all readers) preference for gadobenate dimeglumine was demonstrated for all other qualitative end points. Inter-reader agreement was good for all evaluations (κ = 0.414-0.629). Significantly superior CNR and LBR were determined for gadobenate dimeglumine (P < .019, all readers). Significantly greater morphologic information and lesion enhancement are achieved on brain MR imaging with 0.1-mmol/kg gadobenate dimeglumine compared with gadobutrol at an equivalent dose. |
Author | RUSCALLEDA, J COLOSIMO, C SEIDL, Z YEMEN, B BASTIANELLO, S GOYAL, M ANZALONE, N PARANIAK-GIESZCZYK, B YEUNG, R CITTERIO, A SCHNEIDER, G PASOWICZ, M HERMAN, M VYMAZAL, J MECHL, M |
Author_xml | – sequence: 1 givenname: Z surname: SEIDL fullname: SEIDL, Z organization: Lekarska Fakulta Neurologicka Klinika, Prague, Czech Republic – sequence: 2 givenname: J surname: VYMAZAL fullname: VYMAZAL, J organization: MRI Department Na Homolce Hospital, Prague, Czech Republic – sequence: 3 givenname: N surname: ANZALONE fullname: ANZALONE, N organization: Servizio di Neuroradiologia Ospedale San Raffaele, Milan, Italy – sequence: 4 givenname: A surname: CITTERIO fullname: CITTERIO, A organization: Servizio di Neuroradiologia Ospedale Niguarda Ca' Granda, Milan, Italy – sequence: 5 givenname: G surname: SCHNEIDER fullname: SCHNEIDER, G organization: Department of Diagnostic Radiology Homburg University Hospital, Homburg/Saar, Germany – sequence: 6 givenname: S surname: BASTIANELLO fullname: BASTIANELLO, S organization: Fondazione Istituto Neurologico Casimiro Mondino, Pavia, Italy – sequence: 7 givenname: J surname: RUSCALLEDA fullname: RUSCALLEDA, J organization: Department of Neuroradiology Hospital de la Santa Cruz y San Pablo-Barcelona, Barcelona, Spain – sequence: 8 givenname: M surname: MECHL fullname: MECHL, M organization: Department of Radiology University Hospital Brno, Brno, Czech Republic – sequence: 9 givenname: M surname: GOYAL fullname: GOYAL, M organization: Department of Radiology Seaman Family MR Centre, Foothills Medical Centre, Calgary, Alberta, Canada – sequence: 10 givenname: M surname: HERMAN fullname: HERMAN, M organization: Department of Radiology University Hospital Olomouc, Olomouc, Czech Republic – sequence: 11 givenname: C surname: COLOSIMO fullname: COLOSIMO, C organization: Istituto di Radiologia Policlinico Agostino Gemelli, Rome, Italy – sequence: 12 givenname: M surname: PASOWICZ fullname: PASOWICZ, M organization: John Paul II Hospital, Krakow, Poland – sequence: 13 givenname: R surname: YEUNG fullname: YEUNG, R organization: Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada – sequence: 14 givenname: B surname: PARANIAK-GIESZCZYK fullname: PARANIAK-GIESZCZYK, B organization: NZOZ Slaskie Centrum Diagnostyki Obrazowej Helimed Sp, Katowice, Poland – sequence: 15 givenname: B surname: YEMEN fullname: YEMEN, B organization: Hamilton Health Sciences Corporation Henderson Campus, Hamilton, Ontario, Canada |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25968470$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22383237$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkstuEzEYhS3UiqaFDQ-AvEEqSCm-jOeyAYX0FqkVKASJ3eiPx5O48tjBHkfKs_IyeJpQYMXKls_n8190TtGRdVYh9IqSC06L7D08WH8x4YTzZ2hEK56PK1F9P0IjQisxzikpT9BpCA-EEFEV7Dk6YYyXnPFihH5eOhXwrV6tlcc30DijrY4dnjorle099NpZ_MXADgOeO6OwtrhfK3zv_GbtjFtpiSchqBC6xGPX4k8eErOInfPhI56rEE0fBgHwfbrqwTcVmw3u2jZ6q5sIBk-9C8FtkzJ13Qa8Dqlw-jU0tYy9dwYnMcSwf1EWeoUvdadWJnbaKnz-2NbVfLbAX_vY7N6-QMctmKBeHs4z9O36ajG9Hd99vplNJ3djmWW0HwMB0uRkWRBZNlwKyBopMgkUyooqtqQZ0JZlhJNCKhANa7momALJWEvYkvMz9GHvu4nLTjX7vZl643UHflc70PW_itXreuW2dUkoZyJLBucHA-9-RBX6utNBKmPAKhdDTYWgOc9LSv6PEkZKTkVRJvTdHpXDZr1qnzqipB6CUw_BqR-Dk-DXf8_whP5OSgLeHAAIEkzrwUod_nCiysusIPwXgEHTUg |
CODEN | AAJNDL |
CitedBy_id | crossref_primary_10_3390_app8071138 crossref_primary_10_1002_jmri_27756 crossref_primary_10_1002_jmri_27731 crossref_primary_10_1186_s41747_021_00240_2 crossref_primary_10_1016_j_yrtph_2017_12_016 crossref_primary_10_3174_ajnr_A4468 crossref_primary_10_1002_jmri_24040 crossref_primary_10_1002_jmri_25370 crossref_primary_10_3174_ajnr_A3298 crossref_primary_10_1007_s11547_014_0434_8 crossref_primary_10_1016_j_mric_2012_08_004 crossref_primary_10_2214_AJR_14_14268 crossref_primary_10_1002_jmri_24653 crossref_primary_10_1227_NEU_0b013e3182889ddf crossref_primary_10_1258_ar_2012_120181 crossref_primary_10_1259_bjr_20140526 crossref_primary_10_1097_RMR_0000000000000093 crossref_primary_10_1007_s00261_019_02158_1 crossref_primary_10_3174_ajnr_A4707 crossref_primary_10_3174_ajnr_A3917 crossref_primary_10_3174_ajnr_A4154 crossref_primary_10_1111_bcp_13718 crossref_primary_10_1097_RLI_0b013e31827752b4 crossref_primary_10_5573_ieie_2015_52_2_182 crossref_primary_10_5812_iranjradiol_66054 crossref_primary_10_1002_jmri_29367 crossref_primary_10_1186_s13244_024_01643_6 crossref_primary_10_1097_RLI_0000000000000944 |
Cites_doi | 10.1016/j.acra.2006.02.056 10.1097/00004728-199911001-00021 10.1097/00004424-199712000-00009 10.1097/00004424-200102000-00002 10.3174/ajnr.A1185 10.1097/RLI.0b013e3181feee3a 10.1148/radiol.10090357 10.1007/s00234-003-1128-4 10.1007/s00330-001-1242-9 10.1097/01.rli.0000192421.81037.d5 10.1148/radiology.180.2.2068317 10.1002/jmri.1216 10.3171/jns.2007.106.4.557 10.1097/RLI.0b013e31817d1505 10.1002/cmmi.100 10.1097/RLI.0b013e3181ea703d 10.1148/radiol.2402051266 10.1148/radiol.10100968 10.1097/00002142-200310000-00007 10.1148/radiol.2361040338 10.1002/jmri.21695 10.1097/01.rli.0000184756.66360.d3 10.1097/RLI.0b013e3182145a6c 10.2214/AJR.09.3868 10.1016/0720-048X(95)00679-K 10.1093/ndt/gfp494 10.1097/01.rli.0000197668.44926.f7 10.3174/ajnr.A2010 10.1148/radiol.2301021085 10.1080/02841850903095385 10.1002/jmri.22355 10.3174/ajnr.A2068 |
ContentType | Journal Article |
Copyright | 2015 INIST-CNRS 2012 by American Journal of Neuroradiology 2012 |
Copyright_xml | – notice: 2015 INIST-CNRS – notice: 2012 by American Journal of Neuroradiology 2012 |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 7TK 5PM |
DOI | 10.3174/ajnr.A3033 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Neurosciences Abstracts PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic Neurosciences Abstracts |
DatabaseTitleList | MEDLINE - Academic Neurosciences Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1936-959X |
EndPage | 1058 |
ExternalDocumentID | 10_3174_ajnr_A3033 22383237 25968470 |
Genre | Multicenter Study Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Czech Republic |
GeographicLocations_xml | – name: Czech Republic |
GroupedDBID | --- .55 .GJ 23M 2WC 53G 5GY 5RE 5VS 6J9 AAEJM AAPBV AAUGY ABLYK ABSGY ACGFO ACIWK ACPRK ACRZS ADBBV AENEX AFFNX AFHIN AFRAH AIZTS AJJEV ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW C1A CS3 DIK E3Z EBS EJD EMOBN F5P F9R GX1 H13 INIJC IQODW KQ8 MV1 N9A OK1 P2P P6G R0Z RHF RHI RPM TNE TR2 UDS W8F WOQ WOW X7M ZA5 ZCG ZGI ZXP CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 7TK 5PM |
ID | FETCH-LOGICAL-c441t-a0a0d60b70c8d3c5a4dc54ca1a891e2b14a1f240307cea5d2f3592eac22f02b33 |
IEDL.DBID | RPM |
ISSN | 0195-6108 |
IngestDate | Tue Sep 17 21:35:40 EDT 2024 Sat Aug 17 00:25:06 EDT 2024 Sat Aug 17 03:44:12 EDT 2024 Fri Aug 23 11:01:16 EDT 2024 Tue Aug 27 13:49:23 EDT 2024 Sun Oct 22 16:06:22 EDT 2023 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | Nervous system diseases Intraindividual comparison Radiodiagnosis Gadobenate dimeglumine Central nervous system Gadolinium Tumor Comparative study Encephalon |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c441t-a0a0d60b70c8d3c5a4dc54ca1a891e2b14a1f240307cea5d2f3592eac22f02b33 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-News-2 ObjectType-Feature-3 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
OpenAccessLink | http://www.ajnr.org/content/ajnr/33/6/1050.full.pdf |
PMID | 22383237 |
PQID | 1020831578 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8013254 proquest_miscellaneous_1551636810 proquest_miscellaneous_1020831578 crossref_primary_10_3174_ajnr_A3033 pubmed_primary_22383237 pascalfrancis_primary_25968470 |
PublicationCentury | 2000 |
PublicationDate | 2012-06-01 |
PublicationDateYYYYMMDD | 2012-06-01 |
PublicationDate_xml | – month: 06 year: 2012 text: 2012-06-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Oak Brook, IL |
PublicationPlace_xml | – name: Oak Brook, IL – name: United States |
PublicationTitle | American journal of neuroradiology : AJNR |
PublicationTitleAlternate | AJNR Am J Neuroradiol |
PublicationYear | 2012 |
Publisher | American Society of Neuroradiology |
Publisher_xml | – name: American Society of Neuroradiology |
References | 2018042011152497000_33.6.1050.4 2018042011152497000_33.6.1050.5 2018042011152497000_33.6.1050.6 2018042011152497000_33.6.1050.7 2018042011152497000_33.6.1050.1 2018042011152497000_33.6.1050.25 2018042011152497000_33.6.1050.23 2018042011152497000_33.6.1050.22 2018042011152497000_33.6.1050.29 2018042011152497000_33.6.1050.28 2018042011152497000_33.6.1050.27 2018042011152497000_33.6.1050.26 2018042011152497000_33.6.1050.8 2018042011152497000_33.6.1050.9 2018042011152497000_33.6.1050.20 Elmholdt (2018042011152497000_33.6.1050.24) 2010; 3 Colosimo (2018042011152497000_33.6.1050.3) 2004; 46 Knopp (2018042011152497000_33.6.1050.2) 2004; 230 2018042011152497000_33.6.1050.19 2018042011152497000_33.6.1050.14 2018042011152497000_33.6.1050.36 2018042011152497000_33.6.1050.13 2018042011152497000_33.6.1050.35 2018042011152497000_33.6.1050.12 2018042011152497000_33.6.1050.34 2018042011152497000_33.6.1050.11 Katakami (2018042011152497000_33.6.1050.17) 2011; 46 2018042011152497000_33.6.1050.33 2018042011152497000_33.6.1050.18 2018042011152497000_33.6.1050.16 2018042011152497000_33.6.1050.15 Yuh (2018042011152497000_33.6.1050.21) 1991; 180 2018042011152497000_33.6.1050.37 2018042011152497000_33.6.1050.10 2018042011152497000_33.6.1050.32 2018042011152497000_33.6.1050.31 2018042011152497000_33.6.1050.30 |
References_xml | – ident: 2018042011152497000_33.6.1050.4 doi: 10.1016/j.acra.2006.02.056 – ident: 2018042011152497000_33.6.1050.29 doi: 10.1097/00004728-199911001-00021 – ident: 2018042011152497000_33.6.1050.12 doi: 10.1097/00004424-199712000-00009 – ident: 2018042011152497000_33.6.1050.1 doi: 10.1097/00004424-200102000-00002 – ident: 2018042011152497000_33.6.1050.7 doi: 10.3174/ajnr.A1185 – ident: 2018042011152497000_33.6.1050.14 – ident: 2018042011152497000_33.6.1050.28 doi: 10.1097/RLI.0b013e3181feee3a – ident: 2018042011152497000_33.6.1050.34 doi: 10.1148/radiol.10090357 – volume: 46 start-page: 655 year: 2004 ident: 2018042011152497000_33.6.1050.3 article-title: A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours publication-title: Neuroradiology doi: 10.1007/s00234-003-1128-4 contributor: fullname: Colosimo – volume: 3 start-page: 285 year: 2010 ident: 2018042011152497000_33.6.1050.24 article-title: Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol publication-title: Nephrol Dial Transplant contributor: fullname: Elmholdt – ident: 2018042011152497000_33.6.1050.33 doi: 10.1007/s00330-001-1242-9 – ident: 2018042011152497000_33.6.1050.13 doi: 10.1097/01.rli.0000192421.81037.d5 – volume: 180 start-page: 485 year: 1991 ident: 2018042011152497000_33.6.1050.21 article-title: MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol publication-title: Radiology doi: 10.1148/radiology.180.2.2068317 contributor: fullname: Yuh – ident: 2018042011152497000_33.6.1050.22 doi: 10.1002/jmri.1216 – ident: 2018042011152497000_33.6.1050.6 doi: 10.3171/jns.2007.106.4.557 – ident: 2018042011152497000_33.6.1050.31 doi: 10.1097/RLI.0b013e31817d1505 – ident: 2018042011152497000_33.6.1050.20 doi: 10.1002/cmmi.100 – ident: 2018042011152497000_33.6.1050.37 doi: 10.1097/RLI.0b013e3181ea703d – ident: 2018042011152497000_33.6.1050.5 doi: 10.1148/radiol.2402051266 – ident: 2018042011152497000_33.6.1050.36 doi: 10.1148/radiol.10100968 – ident: 2018042011152497000_33.6.1050.19 doi: 10.1097/00002142-200310000-00007 – ident: 2018042011152497000_33.6.1050.27 doi: 10.1148/radiol.2361040338 – ident: 2018042011152497000_33.6.1050.8 doi: 10.1002/jmri.21695 – ident: 2018042011152497000_33.6.1050.11 doi: 10.1097/01.rli.0000184756.66360.d3 – volume: 46 start-page: 411 year: 2011 ident: 2018042011152497000_33.6.1050.17 article-title: Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase II/III study in patients with known or suspected brain metastases publication-title: Invest Radiol doi: 10.1097/RLI.0b013e3182145a6c contributor: fullname: Katakami – ident: 2018042011152497000_33.6.1050.30 – ident: 2018042011152497000_33.6.1050.35 doi: 10.2214/AJR.09.3868 – ident: 2018042011152497000_33.6.1050.32 doi: 10.1016/0720-048X(95)00679-K – ident: 2018042011152497000_33.6.1050.23 doi: 10.1093/ndt/gfp494 – ident: 2018042011152497000_33.6.1050.10 doi: 10.1097/01.rli.0000197668.44926.f7 – ident: 2018042011152497000_33.6.1050.16 doi: 10.3174/ajnr.A2010 – ident: 2018042011152497000_33.6.1050.18 – ident: 2018042011152497000_33.6.1050.9 – volume: 230 start-page: 55 year: 2004 ident: 2018042011152497000_33.6.1050.2 article-title: Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine publication-title: Radiology doi: 10.1148/radiol.2301021085 contributor: fullname: Knopp – ident: 2018042011152497000_33.6.1050.15 doi: 10.1080/02841850903095385 – ident: 2018042011152497000_33.6.1050.26 doi: 10.1002/jmri.22355 – ident: 2018042011152497000_33.6.1050.25 doi: 10.3174/ajnr.A2068 |
SSID | ssj0005972 |
Score | 2.2532313 |
Snippet | Gadobenate dimeglumine has proved advantageous compared with other gadolinium-based contrast agents for contrast-enhanced brain MR imaging. Gadobutrol is a... BACKGROUND AND PURPOSEGadobenate dimeglumine has proved advantageous compared with other gadolinium-based contrast agents for contrast-enhanced brain MR... BACKGROUND AND PURPOSE:Gadobenate dimeglumine has proved advantageous compared with other gadolinium-based contrast agents for contrast-enhanced brain MR... |
SourceID | pubmedcentral proquest crossref pubmed pascalfrancis |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 1050 |
SubjectTerms | Adult Aged Biological and medical sciences Brain Brain Neoplasms - pathology Contrast Media Czech Republic Electrodiagnosis. Electric activity recording Female Humans Investigative techniques, diagnostic techniques (general aspects) Magnetic Resonance Imaging - methods Male Medical sciences Meglumine - analogs & derivatives Middle Aged Nervous system Observer Variation Organometallic Compounds Radiodiagnosis. Nmr imagery. Nmr spectrometry Reproducibility of Results Sensitivity and Specificity Young Adult |
Title | Does Higher Gadolinium Concentration Play a Role in the Morphologic Assessment of Brain Tumors? Results of a Multicenter Intraindividual Crossover Comparison of Gadobutrol versus Gadobenate Dimeglumine (the MERIT Study) |
URI | https://www.ncbi.nlm.nih.gov/pubmed/22383237 https://search.proquest.com/docview/1020831578 https://search.proquest.com/docview/1551636810 https://pubmed.ncbi.nlm.nih.gov/PMC8013254 |
Volume | 33 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nj9MwELW2e0BICPFNFqgGwQEOaZM4nydUsiwLqGhZdaW9VY7jQFaNUzXNYX8rf4YZJylbhDhwTZzEzow9b-TneYy9jkMhIsQBthsI3_ZjFdgJl74dFugcieKiO5U2_xqeXvifL4PLAxYMZ2EMaV9m5USvqokufxhu5bqS04EnNj2bpzFtEAT-dMRGEedDij7wOhKj2GRECBEbxF1NUgyT_lRc6c1khos2qedgXERvJv3zGwHpzlo0-G-KTtTib6jzT_LkjWh0co_d7WEkzLru3mcHSj9gt-b9RvlD9vO4Vg10JA74SGWbSl22FaR0SlH3pXLhbCWuQcB5vVJQakAsCPMaf3y3IMJsV7UT6gLek5gELNqq3jTv4Fw17Wrb0A0B5hQvvRc_9kkb1YnhmBekNGriiUK6kzykp6hTWUs0eSBmSNt0V5RG8AvHZaW-47KJY4E3pluYby6ASI_Xbx-xi5MPi_TU7nUcbIlga2sLRzh56GSRI-OcS3SKXAa-FK6IE1d5mesLt6C6gE4klQhyr-BB4mFE8LzC8TLOH7NDXWv1lEEQYr4rCu7niYF-ceZKgS1ynog8VJ7FXg3GXK67ch1LTHPI-kuy_tJY32LjPTvvmmIuGGK4diz2cjD8Eqcb7aEIreq2wZd5pM2G69w_2tDmI6dCbxZ70jnL7y_0XmexaM-Ndg2o3Pf-HZwFpux37_VH__3kM3Yb4Z7XEd2es8PtplUvEFJtszEbffkWj81E-gVeaydC |
link.rule.ids | 230,315,733,786,790,891,27957,27958,53827,53829 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbGkAAJcb-UyzgIHuAhbe5NnlDpGB2s0zR1094ix3Eg0DpVkzyMv8qf4Rw7KeuEkOC1di5OP9vfkb9zPsZeRyHnQ-QBlhNw3_IjGVixJ3wrzBEcsfS4yUqbHoaTE__TWXC2xYIuF0aL9kVa9NV80VfFV62tXC7EoNOJDY6m44gOCAJ_cIVdxfnqDrsgvVN2xNqzSdsQIjuITFVS3Cj9Af-mVv0RLtvkn4M7I-KZHNAvbEk3l7zCr5MbW4s_8c7L8skL-9HebXbajcTIUL73mzrtix-Xijz-81DvsFstQ4WRab7LtqS6x65N2zP4--znbikrMPoQ-EgVoQpVNAsYUwKkaqvwwtGcnwOH43IuoVCANBOmJf6nZq2F0bogKJQ5vCefCpg1i3JVvYNjWTXzuqIGDjpBmO6LD9tX2tCiyyCDMX1OkqDCeO2mSFfRS6UNKfCBRCdNZX6RCnk17BYL-QVXZBwLvNGvhaHsDEhPef72ATvZ-zAbT6zWIsISyONqi9vczkI7HdoiyjyBeMtE4Avu8Ch2pJs6PndyKjloD4XkQebmXhC7uNm4bm67qec9ZNuqVPIxgyDEUJrnnp_FmlVGqSM49si8mGehdHvsVYeSZGkqgSQYQRGsEoJVomHVYzsbAFp3xTAzRCZg99jLDlEJzmQ6nuFKlk2FN3PJ9g2X0L_0oXNNj2rI9dgjg8LfT2jh3GPDDXyuO1Al8c0WRJ2uKN6i7Ml_X_mCXZ_MpgfJwf7h56fsBrJK1-jpnrHtetXI58jc6nRHz9NfWz9IPA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LjtMwFLVgkEZIiPejPIaLYAGLtHk3WaHSUmaAjqpRRxrNJnIcBwKtUzXNYvhVfoZ77aS0I8RitsnNw8mxfa58fA9jb6KQ8z7yAMsJuG_5kQys2BO-FeYIjlh63OxKmxyHh6f-57PgbMvqS4v2RVp01XzRVcV3ra1cLkSv1Yn1ppNhRAsEgd9bZnnvOruBfdaN20S9VXfE2rdJWxEiQ4hMZVKcLP0e_6FW3QEO3eShg7MjYppc0LempVtLXuEXyo21xb-452UJ5dacNL7DztvWGCnKz269Trvi16VCj1dq7l12u2GqMDAh99g1qe6z_UmzFv-A_R6VsgKjE4FPVBmqUEW9gCFthFRNNV6YzvkFcDgp5xIKBUg3YVLivzVjLgw2hUGhzOED-VXArF6Uq-o9nMiqnq8rOsFBbxSm--LDjpQ2tmh3ksGQPilJUWG4cVWkq-il0pqU-EDik7oyR6RCfg2jYiG_4ciMbYG3-rUwpZ0B6Sov3j1kp-OPs-Gh1VhFWAL53NriNrez0E77togyTyDuMhH4gjs8ih3ppo7PnZxKD9p9IXmQubkXxC5OOq6b227qeY_YniqVfMIgCDGl5rnnZ7Fml1HqCI4RmRfzLJRuh71ukZIsTUWQBDMpglZC0Eo0tDrsYAdEm1BMN0NkBHaHvWpRlWCPpmUarmRZV3gzl-zfcCj9Twytb3pUS67DHhsk_n1CA-kO6-9gdBNAFcV3zyDydGXxBmlPr3zlS7Y_HY2Tr0fHX56xm0guXSOre8721qtavkACt04PdFf9A1ttSrw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Does+higher+gadolinium+concentration+play+a+role+in+the+morphologic+assessment+of+brain+tumors%3F+Results+of+a+multicenter+intraindividual+crossover+comparison+of+gadobutrol+versus+gadobenate+dimeglumine+%28the+MERIT+Study%29&rft.jtitle=American+journal+of+neuroradiology+%3A+AJNR&rft.au=Seidl%2C+Z&rft.au=Vymazal%2C+J&rft.au=Mechl%2C+M&rft.au=Goyal%2C+M&rft.date=2012-06-01&rft.eissn=1936-959X&rft.volume=33&rft.issue=6&rft.spage=1050&rft.epage=1058&rft_id=info:doi/10.3174%2Fajnr.A3033&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0195-6108&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0195-6108&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0195-6108&client=summon |